112 related articles for article (PubMed ID: 32876438)
1. Potential Doxorubicin-Mediated Dual-Targeting Chemotherapy in FANC/BRCA-Deficient Tumors via Modulation of Cellular Formaldehyde Concentration.
Nakamura J
Chem Res Toxicol; 2020 Oct; 33(10):2659-2667. PubMed ID: 32876438
[TBL] [Abstract][Full Text] [Related]
2. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
3. Detecting the Formation Kinetics of Doxorubicin-DNA Interstrand Cross-link at the Single-Molecule Level and Clinically Relevant Concentrations of Doxorubicin.
Pei Y; Liu Y; Xie C; Zhang X; You H
Anal Chem; 2020 Mar; 92(6):4504-4511. PubMed ID: 32067444
[TBL] [Abstract][Full Text] [Related]
4. The FANC/BRCA Pathway Releases Replication Blockades by Eliminating DNA Interstrand Cross-Links.
Renaudin X; Rosselli F
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32466131
[TBL] [Abstract][Full Text] [Related]
5. A Boolean network model of the FA/BRCA pathway.
Rodríguez A; Sosa D; Torres L; Molina B; Frías S; Mendoza L
Bioinformatics; 2012 Mar; 28(6):858-66. PubMed ID: 22267503
[TBL] [Abstract][Full Text] [Related]
6. Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde.
Ridpath JR; Nakamura A; Tano K; Luke AM; Sonoda E; Arakawa H; Buerstedde JM; Gillespie DA; Sale JE; Yamazoe M; Bishop DK; Takata M; Takeda S; Watanabe M; Swenberg JA; Nakamura J
Cancer Res; 2007 Dec; 67(23):11117-22. PubMed ID: 18056434
[TBL] [Abstract][Full Text] [Related]
7. BRCA-FA pathway as a target for anti-tumor drugs.
Litman R; Gupta R; Brosh RM; Cantor SB
Anticancer Agents Med Chem; 2008 May; 8(4):426-30. PubMed ID: 18473727
[TBL] [Abstract][Full Text] [Related]
8. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
9. Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells.
Saffi J; Agnoletto MH; Guecheva TN; Batista LF; Carvalho H; Henriques JA; Stary A; Menck CF; Sarasin A
DNA Repair (Amst); 2010 Jan; 9(1):40-7. PubMed ID: 19926538
[TBL] [Abstract][Full Text] [Related]
10. Acid-specific formaldehyde donor is a potential, dual targeting cancer chemotherapeutic/chemo preventive drug for FANC/BRCA-mutant cancer.
Ridpath JR; Nakamura J
Genes Environ; 2019; 41():23. PubMed ID: 31890056
[TBL] [Abstract][Full Text] [Related]
11. Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
Rouibah H; Kebsa W; Lahouel M; Zihlif M; Ahram M; Aburmeleih B; Mustafa E; Al-Ameer HJ
Anticancer Agents Med Chem; 2018; 18(3):375-387. PubMed ID: 29318976
[TBL] [Abstract][Full Text] [Related]
12. Site-specific DNA-doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells.
Stuart CH; Horita DA; Thomas MJ; Salsbury FR; Lively MO; Gmeiner WH
Bioconjug Chem; 2014 Feb; 25(2):406-13. PubMed ID: 24450459
[TBL] [Abstract][Full Text] [Related]
13. Analysis of a FANCE Splice Isoform in Regard to DNA Repair.
Bouffard F; Plourde K; Bélanger S; Ouellette G; Labrie Y; Durocher F
J Mol Biol; 2015 Sep; 427(19):3056-73. PubMed ID: 26277624
[TBL] [Abstract][Full Text] [Related]
14. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.
Xie J; Kim H; Moreau LA; Puhalla S; Garber J; Al Abo M; Takeda S; D'Andrea AD
J Clin Invest; 2015 Apr; 125(4):1523-32. PubMed ID: 25751062
[TBL] [Abstract][Full Text] [Related]
15. Poor recognition of O6-isopropyl dG by MGMT triggers double strand break-mediated cell death and micronucleus induction in FANC-deficient cells.
Hashimoto K; Sharma V; Sasanuma H; Tian X; Takata M; Takeda S; Swenberg JA; Nakamura J
Oncotarget; 2016 Sep; 7(37):59795-59808. PubMed ID: 27486975
[TBL] [Abstract][Full Text] [Related]
16. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
18. DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein.
Pichierri P; Averbeck D; Rosselli F
Hum Mol Genet; 2002 Oct; 11(21):2531-46. PubMed ID: 12354779
[TBL] [Abstract][Full Text] [Related]
19. Bilayer Nanocarriers with Protein-Acid Conjugation for Prolonged Release and Enhanced Anticancer Effects.
Hou H; Zhang D; Zeng J; Zhou L; Wang Z; Yao M; Ren J; Hu N; Wang Y
Langmuir; 2019 Mar; 35(10):3710-3716. PubMed ID: 30727729
[TBL] [Abstract][Full Text] [Related]
20. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
